acc2001 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Medulloblastoma |
UW228 |
SPARC OE |
Associated |
3.0 |
21613407
|
acc2002 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Medulloblastoma |
D425 |
SPARC OE |
Associated |
3.0 |
21613407
|
acc2003 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Medulloblastoma |
H2405 |
SPARC OE |
Associated |
3.0 |
21613407
|
acc2004 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Medulloblastoma |
H2411 |
SPARC OE |
Associated |
3.0 |
21613407
|
acc2005 |
STAT3 |
phosphorylation |
Tyr727 |
human |
Medulloblastoma |
Daoy |
SPARC OE |
Associated |
3.0 |
21613407
|
acc2006 |
STAT3 |
phosphorylation |
Tyr727 |
human |
Medulloblastoma |
D283 |
SPARC OE |
Associated |
3.0 |
21613407
|
acc2007 |
STAT3 |
phosphorylation |
Tyr727 |
human |
Medulloblastoma |
UW228 |
SPARC OE |
Associated |
3.0 |
21613407
|
acc2008 |
STAT3 |
phosphorylation |
Tyr727 |
human |
Medulloblastoma |
D425 |
SPARC OE |
Associated |
3.0 |
21613407
|
acc2009 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Colorectal Cancer |
HCT116 |
Doxorubicin |
Enhancing |
5.0 |
20026083
|
acc2010 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Breast Cancer |
MDA-MB-231 |
Doxorubicin |
Enhancing |
5.0 |
20026083
|
acc2011 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Ovarian Cancer |
HeLa |
Doxorubicin |
Enhancing |
5.0 |
20026083
|
acc2012 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Hepatocellular Carcinoma |
HepG2 |
Doxorubicin |
Enhancing |
5.0 |
20026083
|
acc2013 |
PIN1 |
phosphorylation |
Ser115 |
human |
Cholangiocarcinoma |
|
Retinoic acid |
Associated |
4.0 |
34048060
|
acc2014 |
JNK1 |
phosphorylation |
Thr183 |
human |
Hepatocellular Carcinoma |
HuH-7 |
Resveratrol |
Associated |
4.0 |
23437203
|
acc2015 |
JNK1 |
phosphorylation |
Tyr185 |
human |
Hepatocellular Carcinoma |
HuH-7 |
Resveratrol |
Associated |
4.0 |
23437203
|
acc2016 |
JNK2 |
phosphorylation |
Thr183 |
human |
Hepatocellular Carcinoma |
HuH-7 |
Resveratrol |
Associated |
4.0 |
23437203
|
acc2017 |
JNK2 |
phosphorylation |
Tyr185 |
human |
Hepatocellular Carcinoma |
HuH-7 |
Resveratrol |
Associated |
4.0 |
23437203
|
acc2018 |
KIT |
phosphorylation |
Tyr703 |
human |
Lung Cancer |
HCC78 |
Crizotinib + Ponatinib |
Associated |
4.0 |
27068398
|
acc2019 |
KIT |
phosphorylation |
Tyr703 |
human |
Lung Cancer |
CUTO2 |
Crizotinib + Ponatinib |
Associated |
4.0 |
27068398
|
acc2020 |
STAT3 |
phosphorylation |
Tyr705 |
human |
Hepatocellular Carcinoma |
HepG2 xenografts |
Sorafenib + Cucurbitacin B |
Impairing |
5.0 |
33176070
|
acc2021 |
LASP1 |
phosphorylation |
Tyr171 |
human |
Leukemia |
BV173 |
Nilotinib |
Associated |
3.0 |
24913448
|
acc2022 |
AMPK |
phosphorylation |
Thr172 |
human |
Breast Cancer |
MCF7 |
Docosahexaenoic acid (DHA) |
Associated |
4.0 |
24025358
|
acc2023 |
AMPK |
phosphorylation |
Thr183 |
human |
Breast Cancer |
MCF7 |
Docosahexaenoic acid (DHA) |
Associated |
4.0 |
24025358
|
acc2024 |
BIM |
phosphorylation |
unclear |
human |
Leukemia |
SUPT-1 |
Prednisolone |
Impairing |
5.0 |
34007050
|
acc2025 |
ERK1 |
phosphorylation |
Thr202 |
human |
Melanoma |
SB01-VR |
Bafetinib |
Associated |
4.0 |
29717260
|
acc2026 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Melanoma |
SB01-VR |
Bafetinib |
Associated |
4.0 |
29717260
|
acc2027 |
ERK2 |
phosphorylation |
Thr185 |
human |
Melanoma |
SB01-VR |
Bafetinib + Trametinib |
Associated |
4.0 |
29717260
|
acc2028 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Melanoma |
SB01-VR |
Bafetinib + Trametinib |
Associated |
4.0 |
29717260
|
acc2029 |
ERK2 |
phosphorylation |
Thr185 |
human |
Melanoma |
SB01-VR |
Bafetinib |
Associated |
4.0 |
29717260
|
acc2030 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Melanoma |
SB01-VR |
Bafetinib |
Associated |
4.0 |
29717260
|
acc2031 |
ERK1 |
phosphorylation |
Thr202 |
human |
Melanoma |
SB01-VR |
Trametinib |
Associated |
4.0 |
29717260
|
acc2032 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Melanoma |
SB01-VR |
Trametinib |
Associated |
4.0 |
29717260
|
acc2033 |
ERK2 |
phosphorylation |
Thr185 |
human |
Melanoma |
SB01-VR |
Trametinib |
Associated |
4.0 |
29717260
|
acc2034 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Melanoma |
SB01-VR |
Trametinib |
Associated |
4.0 |
29717260
|
acc2035 |
ERK1 |
phosphorylation |
Thr202 |
human |
Melanoma |
SB01-VR |
Bafetinib + Trametinib |
Associated |
4.0 |
29717260
|
acc2036 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Melanoma |
SB01-VR |
Bafetinib + Trametinib |
Associated |
4.0 |
29717260
|
acc2037 |
MEK1 |
phosphorylation |
Ser217 |
human |
Breast Cancer |
MCF7 |
DHA |
Associated |
4.0 |
21771724
|
acc2038 |
MEK1 |
phosphorylation |
Ser221 |
human |
Breast Cancer |
MCF7 |
DHA |
Associated |
4.0 |
21771724
|
acc2039 |
MEK2 |
phosphorylation |
Ser217 |
human |
Breast Cancer |
SK-BR-3 |
DHA |
Associated |
4.0 |
21771724
|
acc2040 |
MEK2 |
phosphorylation |
Ser221 |
human |
Breast Cancer |
SK-BR-3 |
DHA |
Associated |
4.0 |
21771724
|
acc2041 |
ERK1 |
phosphorylation |
Thr202 |
human |
Breast Cancer |
SK-BR-3 |
DHA |
Associated |
4.0 |
21771724
|
acc2042 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Breast Cancer |
SK-BR-3 |
DHA |
Associated |
4.0 |
21771724
|
acc2043 |
ERK2 |
phosphorylation |
Thr185 |
human |
Breast Cancer |
SK-BR-3 |
DHA |
Associated |
4.0 |
21771724
|
acc2044 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Breast Cancer |
SK-BR-3 |
DHA |
Associated |
4.0 |
21771724
|
acc2045 |
MEK2 |
phosphorylation |
Ser217 |
human |
Breast Cancer |
MCF7 |
DHA |
Associated |
4.0 |
21771724
|
acc2046 |
MEK2 |
phosphorylation |
Ser221 |
human |
Breast Cancer |
MCF7 |
DHA |
Associated |
4.0 |
21771724
|
acc2047 |
ERK1 |
phosphorylation |
Thr202 |
human |
Breast Cancer |
MCF7 |
DHA |
Associated |
4.0 |
21771724
|
acc2048 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Breast Cancer |
MCF7 |
DHA |
Associated |
4.0 |
21771724
|
acc2049 |
ERK2 |
phosphorylation |
Thr185 |
human |
Breast Cancer |
MCF7 |
DHA |
Associated |
4.0 |
21771724
|
acc2050 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Breast Cancer |
MCF7 |
DHA |
Associated |
4.0 |
21771724
|